Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open, Single and Multiple Dose, Efficacy and Safety Proof of Principle Study of Liproca Depot, a Controlled Release Formulation of 2-Hydroxyflutamide, Injected Into the Prostate in Patients With Localized Prostate Cancer.

Trial Profile

An Open, Single and Multiple Dose, Efficacy and Safety Proof of Principle Study of Liproca Depot, a Controlled Release Formulation of 2-Hydroxyflutamide, Injected Into the Prostate in Patients With Localized Prostate Cancer.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hydroxyflutamide (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors LIDDS

Most Recent Events

  • 08 Feb 2018 According to a Lidds Pharma media release, results from this and the LPC-003 trials have been published in The Journal of Urology in December 2016.
  • 26 Apr 2012 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
  • 21 Jun 2009 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top